دورية أكاديمية
أعرض في EDS

Advances in the role of circulating tumor cell heterogeneity in metastatic small cell lung cancer.

التفاصيل البيبلوغرافية
العنوان: Advances in the role of circulating tumor cell heterogeneity in metastatic small cell lung cancer.
المؤلفون: Wang Q; Department of Laboratory Medicine, Jiangxi Province's Key Laboratory of Laboratory Medicine The Second Affiliated Hospital of Nanchang University Nanchang Jiangxi China., Tan LM; Department of Laboratory Medicine, Jiangxi Province's Key Laboratory of Laboratory Medicine The Second Affiliated Hospital of Nanchang University Nanchang Jiangxi China.
المصدر: Cancer innovation [Cancer Innov] 2023 Nov 22; Vol. 3 (2), pp. e98. Date of Electronic Publication: 2023 Nov 22 (Print Publication: 2024).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons Australia, Ltd Country of Publication: England NLM ID: 9918713888606676 Publication Model: eCollection Cited Medium: Internet ISSN: 2770-9183 (Electronic) Linking ISSN: 27709183 NLM ISO Abbreviation: Cancer Innov Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Chichester, West Sussex : John Wiley & Sons Australia, Ltd, [2022]-
مستخلص: Small cell lung cancer (SCLC), a highly aggressive malignancy, is rapidly at an extensive stage once diagnosed and is one of the leading causes of death from malignancy. In the past decade, the treatment of SCLC has largely remained unchanged, and chemotherapy remains the cornerstone of SCLC treatment. The therapeutic value of adding immune checkpoint inhibitors to chemotherapy for SCLC is low, and only a few SCLC patients have shown a response to immune checkpoint inhibitors. Circulating tumor cells (CTCs) are tumor cells shed from solid tumor masses into the peripheral circulation and are key to tumor metastasis. Single-cell sequencing has revealed that the genetic profiles of individual CTCs are highly heterogeneous and contribute to the poor outcome and prognosis of SCLC patients. Theoretically, phenotypic analysis of CTCs may be able to predict the diagnostic significance of new potential targets for metastatic tumors. In this paper, we will discuss in depth the heterogeneity of CTCs in SCLC and the value of CTCs for the diagnosis and prognosis of SCLC and as relevant tumor markers in metastatic SCLC.
Competing Interests: The authors declare no conflicts of interest.
(© 2023 The Authors. Cancer Innovation published by John Wiley & Sons Ltd on behalf of Tsinghua University Press.)
References: Lung Cancer. 2014 Aug;85(2):314-9. (PMID: 24882383)
BMC Cancer. 2016 Aug 08;16:614. (PMID: 27501846)
Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):E8379-E8386. (PMID: 27956614)
PLoS One. 2012;7(5):e33788. (PMID: 22586443)
Biomed Pharmacother. 2021 May;137:111314. (PMID: 33581649)
Nat Cancer. 2020 Apr;1:423-436. (PMID: 33521652)
Nat Rev Cancer. 2019 May;19(5):289-297. (PMID: 30926931)
Ann Thorac Surg. 2015 Jun;99(6):1899-905. (PMID: 25678504)
J Hematol Oncol. 2019 Jun 18;12(1):61. (PMID: 31215500)
Nat Med. 2017 Jan;23(1):114-119. (PMID: 27869802)
Acc Chem Res. 2014 Oct 21;47(10):2941-50. (PMID: 25111636)
Cancer Discov. 2021 Apr;11(4):858-873. (PMID: 33811121)
Clin Cancer Res. 2018 Mar 15;24(6):1486-1499. (PMID: 29311117)
BMC Cancer. 2014 Jun 19;14:456. (PMID: 24947048)
Front Oncol. 2020 Sep 15;10:554554. (PMID: 33042837)
Biochim Biophys Acta. 2013 Dec;1836(2):255-72. (PMID: 23796706)
J Thorac Oncol. 2016 Mar;11(3):300-11. (PMID: 26723244)
Mol Clin Oncol. 2020 Mar;12(3):191-195. (PMID: 32064093)
Theranostics. 2018 Feb 7;8(6):1624-1635. (PMID: 29556345)
Expert Opin Pharmacother. 2013 Oct;14(15):2019-31. (PMID: 23901936)
Lab Chip. 2014 Jan 7;14(1):14-23. (PMID: 23835814)
Genet Mol Res. 2015 Dec 22;14(4):17893-903. (PMID: 26782435)
Front Oncol. 2022 Mar 08;12:856575. (PMID: 35356214)
Acta Cytol. 2019;63(6):449-455. (PMID: 31091522)
Cancer Discov. 2014 Jun;4(6):650-61. (PMID: 24801577)
Cells. 2020 Apr 05;9(4):. (PMID: 32260559)
Clin Cancer Res. 2019 Aug 15;25(16):5049-5060. (PMID: 31113842)
Front Oncol. 2021 Jun 25;11:683318. (PMID: 34249732)
Adv Exp Med Biol. 2017;994:43-66. (PMID: 28560667)
Cancers (Basel). 2022 Mar 29;14(7):. (PMID: 35406500)
Nat Rev Cancer. 2019 Oct;19(10):553-567. (PMID: 31455893)
Cancer Immunol Immunother. 2022 Apr;71(4):851-863. (PMID: 34463793)
Genes Dev. 2018 Jul 1;32(13-14):915-928. (PMID: 29945888)
Ann Oncol. 2019 Jul 1;30(7):1114-1120. (PMID: 31020334)
Transl Lung Cancer Res. 2018 Jun;7(3):376-388. (PMID: 30050775)
Nat Med. 2014 Aug;20(8):897-903. (PMID: 24880617)
Oncotarget. 2017 Jul 25;8(30):49044-49052. (PMID: 28467771)
Electrophoresis. 2019 May;40(10):1457-1477. (PMID: 30676660)
Biomicrofluidics. 2020 Aug 19;14(4):041502. (PMID: 32849973)
Cancers (Basel). 2014 Mar 13;6(1):595-624. (PMID: 24633084)
Invest New Drugs. 2017 Jun;35(3):334-344. (PMID: 28299514)
Cancer Cell. 2017 Feb 13;31(2):286-299. (PMID: 28196596)
Int J Mol Sci. 2022 Jul 16;23(14):. (PMID: 35887191)
Cancer Treat Rev. 2013 Nov;39(7):759-72. (PMID: 23375250)
Gut. 2019 Nov;68(11):2019-2031. (PMID: 31227589)
Genome Med. 2020 Mar 19;12(1):31. (PMID: 32192534)
Lung Cancer. 2017 Oct;112:118-125. (PMID: 29191584)
Sci Transl Med. 2010 Mar 31;2(25):25ra23. (PMID: 20424012)
iScience. 2021 Aug 05;24(9):102953. (PMID: 34466783)
Nat Biotechnol. 2014 May;32(5):479-84. (PMID: 24752078)
J Clin Oncol. 2012 Feb 10;30(5):525-32. (PMID: 22253462)
J Thorac Oncol. 2012 Mar;7(3):512-9. (PMID: 22258473)
Cancer Metastasis Rev. 2019 Jun;38(1-2):297-305. (PMID: 31053984)
J Cancer. 2017 Sep 5;8(15):3099-3104. (PMID: 28928901)
J Thorac Oncol. 2022 Mar;17(3):362-387. (PMID: 34808341)
Cancers (Basel). 2020 Nov 26;12(12):. (PMID: 33255978)
J Thorac Oncol. 2015 Sep;10(9):1243-1260. (PMID: 26291008)
Signal Transduct Target Ther. 2021 Nov 22;6(1):404. (PMID: 34803167)
فهرسة مساهمة: Keywords: circulating tumor cell; heterogeneity; immunotherapy; small cell lung cancer; tumor micro‐environment
تواريخ الأحداث: Date Created: 20240701 Latest Revision: 20240702
رمز التحديث: 20240702
مُعرف محوري في PubMed: PMC11212323
DOI: 10.1002/cai2.98
PMID: 38946931
قاعدة البيانات: MEDLINE
الوصف
تدمد:2770-9183
DOI:10.1002/cai2.98